Nordicus Partners Corporation Corporate Update
Orocidin’s QR-01 demonstrates efficacy in two preclinical periodontitis models; micro-CT confirms reduced bone loss Phase IIa clinical trial in patients planned H1 2027 at the University of Copenhagen Bio-Convert receives toxicity waiver from Danish Medicines Agency; GMP manufacturing on track for December 2026 NoviThera establishes biological proof of concept for QR-04 in psoriasis Uplisting application […]